Clinical trials in Oldenburg In Holstein – page 11

212 clinical trials in Oldenburg In Holstein, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Oldenburg In Holstein at a glance

212

clinical trials

Research sites1

Quick filters

212 trials in Oldenburg In Holstein

Open in trial search

Cytomegalovirus immunisation

Not recruiting

Efficacy, Safety, and Immunogenicity of mRNA-1647 Vaccine in Preventing Primary Cytomegalovirus Infection in CMV-Seronegative Females Aged 16-40

Registered drug

Efficacy, Safety, and Immunogenicity of mRNA-1647 Vaccine in Preventing Primary Cytomegalovirus Infection in CMV-Seronegative Females Aged 16-40

Registered drug

Germany

Participants:0–17 years · 18–64 years · Healthy volunteers
Substances:Sodium Chloride
Sponsor:Moderna Inc.

Contact Research Centre

Type 2 diabetes mellitus

Not recruiting

A study comparing cagrilintide and semaglutide combination to semaglutide, cagrilintide, and placebo in adults with type 2 diabetes on metformin

Registered drug

A study comparing cagrilintide and semaglutide combination to semaglutide, cagrilintide, and placebo in adults with type 2 diabetes on metformin

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Cagrilintide
Sponsor:Novo Nordisk A/S

Contact Research Centre

Chronic kidney disease+1

Not recruiting

A study of ziltivekimab compared to placebo in people with heart and blood vessel disease, chronic kidney disease and inflammation

Investigational

A study of ziltivekimab compared to placebo in people with heart and blood vessel disease, chronic kidney disease and inflammation

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Ziltivekimab
Sponsor:Novo Nordisk A/S

Contact Research Centre

Hidradenitis

Not recruiting

Evaluation of CIT-013 at two dose levels compared to placebo for treating moderate to severe Hidradenitis Suppurativa

Investigational

Evaluation of CIT-013 at two dose levels compared to placebo for treating moderate to severe Hidradenitis Suppurativa

Investigational

Germany

Participants:18–64 years · 65+ years
Sponsor:Citryll B.V.

Contact Research Centre

Type 2 diabetes mellitus

Not recruiting

Study of oral and injectable NNC0487-0111 (Amycretin) to find the best dose for blood sugar control in adults with type 2 diabetes taking metformin with or without SGLT2 inhibitor

Registered drug

Study of oral and injectable NNC0487-0111 (Amycretin) to find the best dose for blood sugar control in adults with type 2 diabetes taking metformin with or without SGLT2 inhibitor

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Metformin Embonate
Sponsor:Novo Nordisk A/S

Contact Research Centre

Type 2 diabetes mellitus

Not recruiting

Study of LY3457263 compared to placebo in adults with type 2 diabetes who are taking semaglutide or tirzepatide but have not reached their blood sugar goals

Investigational

Study of LY3457263 compared to placebo in adults with type 2 diabetes who are taking semaglutide or tirzepatide but have not reached their blood sugar goals

Investigational

Germany

Participants:18–64 years
Substances:Tirzepatide
Sponsor:Eli Lilly & Co.

Contact Research Centre

Obesity+1

Not recruiting

Study of cagrilintide for weight reduction in adults with overweight or obesity when combined with lifestyle changes

Investigational

Study of cagrilintide for weight reduction in adults with overweight or obesity when combined with lifestyle changes

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Cagrilintide
Sponsor:Novo Nordisk A/S

Contact Research Centre

Hypertension

Not recruiting

Study of orforglipron in people with high blood pressure who are overweight or have obesity

Investigational

Study of orforglipron in people with high blood pressure who are overweight or have obesity

Investigational

Germany

Participants:18–64 years
Sponsor:Eli Lilly & Co.

Contact Research Centre

Non-small cell lung cancer+5

Not recruiting

Study of sacituzumab govitecan and zimberelimab treatment before and after surgery for patients with resectable non-small cell lung cancer

Registered drugNo placebo

Study of sacituzumab govitecan and zimberelimab treatment before and after surgery for patients with resectable non-small cell lung cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Zimberelimab
Sponsor:AIO-Studien gGmbH

Contact Research Centre

Cognitive disorder

Not recruiting

Study on the Effects of Donepezil on Cognitive and Motor Functions in Elderly Patients with Neurological Disorders

Registered drug

Study on the Effects of Donepezil on Cognitive and Motor Functions in Elderly Patients with Neurological Disorders

Registered drug

Germany

Participants:18–64 years · 65+ years · Healthy volunteers
Substances:Donepezil Hydrochloride
Sponsor:Carl Von Ossietzky Universitaet Oldenburg

Contact Research Centre

Obesity+1

Not recruiting

Study on Maridebart Cafraglutide for Adults with Type 2 Diabetes and Obesity or Overweight

Investigational

Study on Maridebart Cafraglutide for Adults with Type 2 Diabetes and Obesity or Overweight

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Maridebart Cafraglutide
Sponsor:Amgen Inc.

Contact Research Centre

Obesity+1

Not recruiting

Study on the Effectiveness and Safety of Maridebart Cafraglutide for Adults with Obesity or Overweight Without Type 2 Diabetes

Investigational

Study on the Effectiveness and Safety of Maridebart Cafraglutide for Adults with Obesity or Overweight Without Type 2 Diabetes

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Maridebart Cafraglutide
Sponsor:Amgen Inc.

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Oldenburg In Holstein

What the registry says about research in the country

01 Metabolic Disorders

Innovative clinical trials focusing on Type 2 Diabetes management and treatments, including studies of novel weekly insulin alternatives and oral medications for glycemic control.

Glycemic Control Studies
Insulin Alternatives Research
Cardiovascular Outcomes

Multiple studies evaluating new therapeutic approaches for better diabetes management and reducing cardiovascular risks.

02 Weight Management

Comprehensive research into obesity treatment and weight-related conditions, examining new therapeutic combinations and their effects on weight loss and associated health conditions.

Weight Loss Interventions
Obesity Medications
Comorbidity Management

Studies focusing on innovative approaches to weight management and treating obesity-related health complications.

03 Cardiovascular Health

Research examining treatments for atherosclerotic cardiovascular disease and related conditions, with emphasis on preventing major adverse cardiovascular events.

Cardiovascular Risk Reduction
Lipid Management
Preventive Therapies

Trials evaluating new medications for improving cardiovascular outcomes in high-risk patients.

04 Gastrointestinal Studies

Clinical investigations of treatments for Crohn's Disease and other digestive conditions, focusing on long-term efficacy and safety of new therapeutic approaches.

Inflammatory Bowel Disease
Long-term Treatment Outcomes
Disease Management

Studies aimed at improving quality of life for patients with chronic gastrointestinal conditions.

05 Oncology Research

Advanced studies in colorectal cancer treatment and management, including innovative approaches to Stage II and III cancer therapy.

Cancer Treatment Protocols
Disease-Free Survival
Adjuvant Therapy

Trials evaluating new treatment strategies for improving outcomes in cancer patients.

Back to Germany All countries